Skip to content

SG&A at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$493.7M+24.5%
Teledyne Technologies logo
Teledyne TechnologiesTDY
$237.4M+1.5%
Corteva logo
CortevaCTVA
$725M+8.0%
Cummins logo
CumminsCMI
$845M+9.6%
Medtronic logo
MedtronicMDT
$3.06B+12.4%
Gartner logo
GartnerIT
$726.35M-0.5%

Other financials

Income statement

See full
Revenue$276.8M+234%
Gross profit$46.5M+158%
Operating income-$45.7M-77,478%
Net income-$12.4M-263%
EPS (diluted)-$0.05-150%

Balance sheet

See full
Cash & equivalents$681.7M+215%
Total debt$2.3B+82.2%
Total equity$5.3B+178%
Total assets$7.7B+131%

Cash flow

See full
Operating cash flow$34.6M+24.9%
CapEx$4.9M+28.6%
Free cash flow$29.7M+24.3%

Valuation

See full
Market cap$6.31B+43.2%
Enterprise value$7.92B+45.4%
P/E13.6×+1.1×
P/S9.3×+4.7×

Profitability

See full
Gross margin27.4%-17.6pp
Operating margin5.5%-31.6pp
Net margin68.6%+31.6pp
FCF margin37.9%+19.9pp

Returns & leverage

See full
Return on equity12.8%-6.1pp
Debt / equity0.4×-0.2×
Current ratio2.5×-0.2×

Where this comes from

Reported directly by Rayonier in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Rayonier’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rayonier's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rayonier's SG&A?
Rayonier (RYN) reported SG&A of $21.67M in Q1 2026.
How has Rayonier's SG&A changed year-over-year?
Rayonier's SG&A increased by 29.8% year-over-year, from $16.69M to $21.67M.
What is the long-term trend for Rayonier's SG&A?
Over 4 years (2021 to 2025), Rayonier's SG&A has grown at a 3.6% compound annual growth rate (CAGR), from $57.79M to $66.69M.
What does SG&A mean?
Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.